681 related articles for article (PubMed ID: 29377877)
21. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
[TBL] [Abstract][Full Text] [Related]
22. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.
Johnson RJ; Clatworthy MR; Birch R; Hammad A; Bradley JA
Transplantation; 2009 Jul; 88(1):77-82. PubMed ID: 19584684
[TBL] [Abstract][Full Text] [Related]
23. A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients.
Reischig T; Vlas T; Kacer M; Pivovarcikova K; Lysak D; Nemcova J; Drenko P; Machova J; Bouda M; Sedivcova M; Kormunda S
J Am Soc Nephrol; 2023 May; 34(5):920-934. PubMed ID: 36749127
[TBL] [Abstract][Full Text] [Related]
24. Different impact of rATG induction on CMV infection risk in D+R- and R+ KTRs.
Kaminski H; Jarque M; Halfon M; Taton B; Di Ascia L; Pfirmann P; Visentin J; Garrigue I; Déchanet-Merville J; Moreau JF; Crespo E; Montero N; Melilli E; Meneghini M; Pascual M; Couzi L; Manuel O; Bestard O; Merville P
J Infect Dis; 2019 Jul; 220(5):761-771. PubMed ID: 31157865
[TBL] [Abstract][Full Text] [Related]
25. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis.
Liverman R; Serluco A; Nance G; George R; Rodriguez DS; Deshpande S; Mao C; Garro R; Yildirim I
Pediatr Transplant; 2023 Jun; 27(4):e14493. PubMed ID: 36945819
[TBL] [Abstract][Full Text] [Related]
26. Low-dose valganciclovir prohylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti-thymocyte globulin.
Eriksson M; Jokinen JJ; Söderlund S; Hämmäinen P; Lommi J; Lemström K
Transpl Infect Dis; 2018 Jun; 20(3):e12868. PubMed ID: 29512249
[TBL] [Abstract][Full Text] [Related]
27. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
Myhre HA; Haug Dorenberg D; Kristiansen KI; Rollag H; Leivestad T; Asberg A; Hartmann A
Transplantation; 2011 Jul; 92(2):217-23. PubMed ID: 21685829
[TBL] [Abstract][Full Text] [Related]
28. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
[TBL] [Abstract][Full Text] [Related]
29. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
Lo A; Stratta RJ; Egidi MF; Shokouh-Amiri MH; Grewal HP; Kisilisik AT; Trofe J; Alloway RR; Gaber LW; Gaber AO
Transpl Infect Dis; 2001 Mar; 3(1):8-15. PubMed ID: 11429034
[TBL] [Abstract][Full Text] [Related]
30. Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus.
Devresse A; Leruez-Ville M; Scemla A; Avettand-Fenoel V; Morin L; Lebreton X; Tinel C; Amrouche L; Lamhaut L; Timsit MO; Zuber J; Legendre C; Anglicheau D
Transpl Infect Dis; 2018 Apr; 20(2):e12846. PubMed ID: 29360195
[TBL] [Abstract][Full Text] [Related]
31. Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+/R- kidney transplant patients receiving thymoglobulin induction.
Luan FL
Transplant Proc; 2013; 45(1):175-7. PubMed ID: 23267799
[TBL] [Abstract][Full Text] [Related]
32. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients.
Lisboa LF; Preiksaitis JK; Humar A; Kumar D
Transplantation; 2011 Nov; 92(9):1063-8. PubMed ID: 21878838
[TBL] [Abstract][Full Text] [Related]
33. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A
BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027
[TBL] [Abstract][Full Text] [Related]
34. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
Chiereghin A; Potena L; Borgese L; Gibertoni D; Squarzoni D; Turello G; Petrisli E; Piccirilli G; Gabrielli L; Grigioni F; Lazzarotto T
J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29305542
[TBL] [Abstract][Full Text] [Related]
35. Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients.
Schaenman J; Phonphok K; Spanuchart I; Duong T; Sievers TM; Lum E; Reed EF; Bunnapradist S
Transpl Infect Dis; 2021 Feb; 23(1):e13457. PubMed ID: 32892447
[TBL] [Abstract][Full Text] [Related]
36. Post-renal transplant cytomegalovirus infection: study of risk factors.
Kute VB; Vanikar AV; Shah PR; Gumber MR; Patel HV; Godara SM; Munjappa BC; Sainaresh VV; Engineer DP; Jain SH; Modi PR; Shah VR; Trivedi VB; Trivedi HL
Transplant Proc; 2012 Apr; 44(3):706-9. PubMed ID: 22483473
[TBL] [Abstract][Full Text] [Related]
37. The impact of viral load and time to onset of cytomegalovirus replication on long-term graft survival after kidney transplantation.
Reischig T; Kacer M; Hruba P; Jindra P; Hes O; Lysak D; Bouda M; Viklicky O
Antivir Ther; 2017; 22(6):503-513. PubMed ID: 28091392
[TBL] [Abstract][Full Text] [Related]
38. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.
Huurman VA; Kalpoe JS; van de Linde P; Vaessen N; Ringers J; Kroes AC; Roep BO; De Fijter JW
Diabetes Care; 2006 Apr; 29(4):842-7. PubMed ID: 16567825
[TBL] [Abstract][Full Text] [Related]
39. Burden of cytomegalovirus DNAemia among pediatric renal transplant patients on antiviral prophylaxis: A hospital-based analysis.
Mehta K; Al-Yabes O; Allen A; Williams A; Petrich A; Langlois V; Hébert D; Allen U
Pediatr Transplant; 2020 Feb; 24(1):e13650. PubMed ID: 31891234
[TBL] [Abstract][Full Text] [Related]
40. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
